All In Biotech

Free tool

FAERS Monitor: Selarsdi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761343 or its brand name (Selarsdi, Ustekinumab-Aekn). Reports on generic versions are filed under their own applications.

Reports

6

Serious

3

50% of reports

Hospitalization

2

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • vomiting2
  • abdominal discomfort1
  • abdominal pain upper1
  • alopecia1
  • anti-cyclic citrullinated peptide antibody positive1
  • arthralgia1
  • arthropathy1
  • asthenia1
  • blood cholesterol increased1
  • brain fog1
  • bursitis1
  • c-reactive protein increased1
  • cerebral venous sinus thrombosis1
  • confusional state1
  • decreased appetite1

Reports by year received

View as table
YearReports
20253
20263

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,153 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cerebral venous sinus thrombosis14157.6693.81,037
anti-cyclic citrullinated peptide antibody positive1489.381.8121
bursitis1288.948.371
brain fog1223.737.455
c-reactive protein increased196.316.123
blood cholesterol increased175.212.618
arthropathy163.110.515
confusional state121.73.65
abdominal discomfort120.93.54
alopecia117.93.04
abdominal pain upper117.02.83
decreased appetite115.12.53
vomiting214.94.814
asthenia19.31.61
arthralgia18.41.41

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.